Mobilizing the
Human Immune System
to Combat Disease
HiFiBiO Therapeutics is an emerging multinational company that seeks to transform patient care.
HiFiBiO Therapeutics is an emerging multinational company that seeks to transform patient care.
CAMBRIDGE, Mass. – May 9th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Lynn Bodarky as a Senior Vice President to oversee the company’s business development and alliance management activities, reporting directly to HiFiBiO’s President and CEO, Dr. Liang Schweizer. “We are very excited to bring on board an … Continued
CAMBRIDGE, MA – April 27th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that clinical trial investigator, Alexander I Spira, MD, PhD, FACP, Co-Director of the Virginia Cancer Specialists (VCS) Research Institute and Director of the Thoracic and Phase I Program, will present a Trials in Progress Poster for HFB200301 on Sunday, … Continued
CAMBRIDGE, Mass. – May 9th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, today announced the appointment of Lynn Bodarky as a Senior Vice President to oversee the company’s business development and alliance management activities, reporting directly to HiFiBiO’s President and CEO, Dr. Liang Schweizer. “We are very excited to bring on board an … Continued
• Comprehensive DIS™ platform IP: Single Cell (CelliGo™) and AI Data Analytics (Absolution™)
• High quality single cell data collection from cancer and autoimmune diseases
• Discovery of therapeutics based in immune modulation rather than disease types
• Live single B cell screening (5K cells/second) for unprecedented deep immune repertoire mining
• Single cell analysis and data intelligence for indication and biomarker-driven patient selection
• Single cell immune profiling with machine learning to identify disease relevant novel targets
• Next generation bi-specific antibody platforms
• High quality antibody drug candidates
• Enhanced patient responses
• Shortened drug discovery and clinical development timelines with reduced resources
• Comprehensive DIS™ platform IP: Single Cell (CelliGo™) and AI Data Analytics (Absolution™)
• High quality single cell data collection from cancer and autoimmune diseases
• Discovery of therapeutics based in immune modulation rather than disease types
• Live single B cell screening (5K cells/second) for unprecedented deep immune repertoire mining
• Single cell analysis and data intelligence for indication and biomarker-driven patient selection
• Single cell immune profiling with machine learning to identify disease relevant novel targets
• Next generation bi-specific antibody platforms
• High quality antibody drug candidates
• Enhanced patient responses
• Shortened drug discovery and clinical development timelines with reduced resources